Drug-resistant TB: Deadly, costly and in need of a vaccine

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 110, Issue 3, 2015, Pages 186-191

  Manjelievskaia, Janna ^a   Erck, Dara ^b   Piracha, Samina ^b   Schrager, Lewis ^c  

^a Epidemiology   (United States)

^b Office of External Affairs   (United States)

^c Off of Clinical Laboratory Affairs   (United States)

Author keywords

Extensively drug resistant TB; Multidrug resistant TB; Public health; Tuberculosis; Vaccines

Indexed keywords

BCG VACCINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL TRANSMISSION; BCG VACCINATION; COST CONTROL; COST OF ILLNESS; DISEASE ELIMINATION; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE COST; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; DISEASE ERADICATION; ECONOMICS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

DISEASE ERADICATION; HEALTH CARE COSTS; HUMANS; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84959880232     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/trw006     Document Type: Review

References (36)

1. WHO. Global tuberculosis report 2015. Geneva: World Health Organization; 2015. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1 [accessed 28 August 2015].
2. Statistics South Africa. Causes of Death 2013. Pretoria: Statistics South Africa; 2015. http://www.statssa.gov.za/?page_id=737&id=3 [accessed 17 August 2015].
3. Moran M, Guzman J, Chapman N et al. G-Finder 2014: Neglected disease research and development: Emerging trends. Sydney: Policy Cures; 2014. http://www.policycures.org/downloads/Y7%20GFINDER%20full%20report%20web%20.pdf [accessed 15 August 2015].
4. WHO. Trade, foreign policy, diplomacy and health. Tuberculosis (TB). Geneva: World Health Organization. http://www.who.int/trade/ glossary/story092/en/ [accessed 17 August 2015].
5. Marks SM, Flood J, Seaworth B et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis 2014; 20:812-20.
6. Marais BJ, Mlambo CK, Rastogi N et al. Epidemic spread of multidrugresistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol 2013;51:1818-25.
7. Pooran A, Pieterson E, Davids M et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One 2013;8:e54587.
8. Wilkie MEM, McShane H. TB vaccine development: where are we and why is it so difficult? Thorax 2015;70:299-301.
9. Cole ST, Eisenach KD, McMurray DN, Jacobs WR (editors). Tuberculosis and the tubercle bacillus.Washington, DC: ASM Press; 2005, p. 129-31.
10. Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis. BMJ 2015;350:h882.
11. CDC. Tuberculosis (TB): Fact sheet. Trends in Tuberculosis, 2014. Atlanta: Centers for Disease Control and Prevention; http://www.cdc. gov/tb/publications/factsheets/statistics/tbtrends.htm [accessed 28 October 2015].
12. WHO. What is TB? How is it treated? Geneva: World Health Organization; 2015. http://www.who.int/features/qa/08/en/ [accessed 28 October 2015].
13. Hedgpeth D, Gebelhoff R. CDC, state officials track down people possibly exposed to rare form of TB. Washington Post. 9 June 2015. https://www.washingtonpost.com/national/health-science/womanwith- rare-form-of-tb-treated-at-nih-in-bethesda/2015/06/09/7f779e60-0e97-11e5-a0dc-2b6f404ff5cf_story.html [accessed 28 October 2015].
14. Belt D. Woman with rare, drug-resistant form of TB treated at NIH. Bethesda-Chevy Chase Patch 10 June 2015. http://patch.com/ maryland/bethesda-chevychase/woman-rare-drug-resistant-formtb- treated-nih [accessed 28 October 2015].
15. Grady D. Tuberculosis case prompts search for patient's fellow airline passengers. The New York Times 8 June 2015: A8. http://www. nytimes.com/2015/06/09/science/tuberculosis-case-promptssearch- for-patients-fellow-airline-passengers.html?_r%BC0&_r=0 [accessed 28 October 2015].
16. Cole ST, Eisenach KD, McMurray DN, Jacobs WR (editors). Tuberculosis and the tubercle bacillus. Washington, DC: ASM Press; 2005, p. 115.
17. Cox E, Laessig K. FDA approval of bedaquiline: the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 2014;371:689-91.
18. Committee for Medicinal Products for Human Use (CHMP). Summaryof opinion (initial authorisation): Deltyba (delamanid). London: European Medicines Agency; 2013. EMA/CHMP/713909/2013. http://www.ema. europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_ Initial_authorisation/human/002552/WC500155458.pdf [accessed 28 October 2015].
19. Prabowo SA, Groschel MI, Schmidt EDL et al. Targeting multidrugresistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013;202:95-104.
20. Sturdy A, Goodman A, Jose RJ et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011;66:1815-20.
21. Mitnick C, Bayona J, Palacios E et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. NEJM 2003;348:119-28.
22. Barker LF, Leadman AE, Clagett B. The challenges of developing new tuberculosis vaccines. Health Affairs 2011;30:1073-9.
23. Tameris M, McShane H, McClain B et al. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis 2013;93:143-9.
24. CDC. Ebola (Ebola Virus Disease). 2014 Ebola Outbreak inWest Africa -Case Counts. Atlanta: Centers for Disease Control and Prevention. http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/casecounts. html [accessed 17 August 2015].
25. Campos LM, Rissetto CL, Helland R. Global Regulatory Enforcement Law Blog. Government Contracts & Grants. FY 2015 Ebola federal funding: Congressional increases and program support. Pittsburg:Reed Smith. http://www.globalregulatoryenforcementlawblog.com/2014/12/articles/government-contracts/fy-2015-ebola-federal- funding-congressional-increases-and-program-support/ [accessed 20 August 2015].
26. Frick M. 2014 Report on TB Research Funding Trends, 2005-2013. 2nd ed. New York: Treatment Action Group (TAG); 2015. http:// www.treatmentactiongroup.org/sites/g/files/g450272/f/201505/ TAG_2014_TB_Funding_Report_2nd_Ed.pdf [accessed 20 August 2015].
27. WHO. Emergencies preparedness, response. Ebola response: What needs to happen in 2015. Geneva: World Health Organization; 2015. http://www.who.int/csr/disease/ebola/one-year-report/response-in-2015/en/ [accessed 17 August 2015].
28. WHO. Tuberculosis (TB): The End TB strategy. Geneva: World Health Organization; 2016. http://www.who.int/tb/strategy/end-tb/en/ [accessed 16 November 2015].
29. Knight GM, Griffiths UK, Sumner T et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A 2014;111:15520-5.
30. Richter SS, Diekema DJ, Heilmann KP et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13- valent conjugate vaccine in the United States. Antimicrob Agents Chemother 2014;58:6484-9.
31. Dagan R, Juergens C, Trammel J et al. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible streptococcus pneumonia. J Infect Dis 2015;211:1144-53.
32. IHME. Financing Global Health 2014. Shifts in Funding as the MDG Era Closes. Seattle: Institute for Health Metrics and Evaluation; 2015. http:// www.healthdata.org/sites/default/files/files/policy_report/2015/ FGH2014/IHME_PolicyReport_FGH_2014_0.pdf [accessed 20 August 2015].
33. GHTC. 2015 policy report: Meeting the challenge, seizing the opportunity. Washington, DC: Global Health Technologies Coalition. http://www.ghtcoalition.org/policy-report/2015/lessons-learnedfrom- ebola.php [accessed 20 August 2015].
34. Moran M, Chapman N, Howard R et al. Tuberculosis: The Last Mile. Sydney: Policy Cures; 2014. http://policycures.org/downloads/GF_ TBreport_final_web.pdf [accessed 20 August 2015].
35. Ditkowsky JB, Schwartzmann K. Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa- implication for clinical trials: A decision analysis. PLoS ONE 2014;9:e83526.
36. Ahsan MJ. Recent advances in the development of vaccines for tuberculosis. Ther Adv Vaccines 2015;3:66-75.